Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication

Acta Psychiatrica Scandinavica

Volumn 114, Issue 1, 2006, Pages 21-26

  Nesvag R ^a   Hendset, M ^a   Refsum, H ^a   Tanum, L ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

Author keywords

Prolonged action preparations; Risperidone; Schizophrenia

Indexed keywords

PALIPERIDONE; RISPERIDONE;

ADOLESCENT; ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 33745068503     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2006.00840.x     Document Type: Article

References (31)

1. Remington G Kapur S. Atypical antipsychotics: are some more atypical than others Psychopharmacology (Berl) 2000 148: 3 15.
2. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002 47: 27 38.
3. Burns T Christova L Cooper S et al. Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: a naturalistic cohort study. Acta Psychiatr Scand 2006 113: 126 134.
4. Kane JM Eerdekens M Lindenmayer JP Keith SJ Lesem M Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003 160: 1125 1132.
5. Chue P Eerdekens M Augustyns I et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005 15: 111 117.
6. Marder SR Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994 151: 825 835.
7. Knox ED Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther 2004 26: 1994 2002.
8. Scordo MG Spina E Facciolà G Avenoso A Johansson I Dahl ML. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 1999 147: 300 305.
9. Bork JA Rogers T Wedlund PJ de Leon J. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999 60: 469 476.
10. Aravagiri M Marder SR Nuechterlein KH Gitlin MJ. Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit 2003 25: 657 664.
11. Castberg I Spigset O. Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. Ther Drug Monit 2005 27: 103 106.
12. Nesvåg R Tanum L. Therapeutic drug monitoring of patients on risperidone depot. Nord J Psychiatry 2005 59: 51 55.
13. Eerdekens M Van Hove I Remmerie B Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004 70: 91 100.
14. Tuninger E Levander S. Large variations of plasma levels during maintenance treatment with depot neuroleptics. Br J Psychiatry 1996 169: 618 621.
15. Ulrich S Wurthmann C Brosz M Meyer FP. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 1998 34: 227 263.
16. Jann MW Ereshefsky L Saklad SR. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 1985 10: 315 333.
17. Spina E Avenoso A Facciolà G et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 2001 153: 238 243.
18. Ereshefsky L Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone. Drugs R D 2005 6: 129 137.
19. Alfaro CL Lam YW Simpson J Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 2000 40: 58 66.
20. Nordström AL Farde L Wiesel FA et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993 33: 227 235.
21. Nyberg S Eriksson B Oxentstierna G Halldin C Farde L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999 156: 869 875.
22. Gefvert O Eriksson B Persson P et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal ConstaTM) in patients with schizophrenia. Int J Neuropsychopharmacol 2005 8: 27 36.
23. Van Beijsterveldt LE Geerts RJ Leysen JE et al. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl) 1994 114: 53 62.
24. Aravagiri M Marder SR. Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats. Psychopharmacology (Berl) 2002 159: 424 431.
25. Remington GJ Adams ME. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 1995 40: S5 S11.
26. Kane JM Aguglia E Altamura AC et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998 8: 55 66.
27. Riedel M Schwarz MJ Strassnig M et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 2005 255: 261 268.
28. Taylor DM Young CL Mace S Patel MX. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 2004 65: 1076 1083.
29. Lasser RA Bossie CA Gharabawi GM Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004 19: 219 225.
30. Hosalli P Davis JM. Depot risperidone for schizophrenia. Cochrane Database Syst Rev 2003 CD004161.
31. Kapur S Zipursky RB Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999 156: 286 293.